The CDK4/6-targeted inhibitor treatment of advanced hormone-resistant and metastatic ER+ breast cancer has shown significant clinical benefit when combined with aromatase inhibitors (AIs) or selective estrogen receptor degraders (SERDs) [244]. This evidence concerns the gene ESR1 and breast carcinoma.